{"links":{"html":"https://www.erudio.com/reports/interpath-002-nct06077760","json":"https://www.erudio.com/reports/interpath-002-nct06077760.json","markdown":"https://www.erudio.com/reports/interpath-002-nct06077760.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"interpath-002-06077760"}},"request":"https://www.erudio.com/contact?report=interpath-002-06077760"},"offer":{"cited_commentary_sources":19,"verified_hcp_statements":36,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":750,"identity_verified_people":6,"optional":true,"price_per_verified_person_usd":15,"price_usd":90,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"interpath-002-nct06077760"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=interpath-002-06077760","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/interpath-002-nct06077760","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_rule":"Focused: 1–150 verified statements","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-29T04:26:11.121985Z","notify_subscribers":false,"status":"corrected","summary":"Corrected to match the delivered report: per-finding counts; the limitations; the sample findings; source quotations and links in the paid report. The trial's name is spelled as its investigators write it, “INTerpath-002” (NCT06077760), outside quotations (was “Interpath”). The trial's registration date is now stated."},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":9,"no_commentary_found":3},"aspects":[{"claim_count":0,"coverage":"no_commentary_found","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":0,"title":"Primary endpoint: Disease- Free Survival (DFS)"},{"claim_count":0,"coverage":"no_commentary_found","id":"T2","registry_field":"outcomesModule.secondaryOutcomes","source_count":0,"title":"Secondary endpoints"},{"claim_count":9,"coverage":"discussed","id":"T3","registry_field":"conditionsModule","source_count":7,"title":"Population and setting"},{"claim_count":8,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":6,"title":"The comparison"},{"claim_count":0,"coverage":"no_commentary_found","id":"T5","registry_field":"outcomesModule","source_count":0,"title":"Safety and tolerability"},{"claim_count":4,"coverage":"discussed","id":"T6","registry_field":"designModule","source_count":5,"title":"Design and conduct"},{"claim_count":6,"coverage":"discussed","id":"A1","source_count":3,"title":"Cross-tumor rationale and the unresolved cure question"},{"claim_count":3,"coverage":"discussed","id":"A2","source_count":2,"title":"Comparative benefit versus neoadjuvant treatment"},{"claim_count":3,"coverage":"discussed","id":"A3","source_count":2,"title":"Conceptual relevance and evidentiary credibility"},{"claim_count":6,"coverage":"discussed","id":"A4","source_count":3,"title":"Administration burden and cross-center recruitment"},{"claim_count":1,"coverage":"discussed","id":"A5","source_count":1,"title":"An unspecified ICI-like drug combined with mRNA-4157"},{"claim_count":7,"coverage":"discussed","id":"A6","source_count":4,"title":"Personalized-vaccine comparisons with CAN-2409 and TIL approaches"}],"counts":{"cited_sources":20,"claims_by_expression_type":{"comparison":3,"interpretation":5,"opinion":6,"primary_context":1,"question":5,"restatement":5,"uncertainty":1,"unspecified":10},"claims_by_kind":{"attributed_opinion":9,"interpretation":1,"protocol_statement":1,"source_observation":25},"clinician_statements":8,"evidence_units":32,"findings":6,"organisational_accounts":2,"people_cited":11,"people_identity_verified":6,"people_total":14,"screened_sources":50,"verified_claims":36},"depth":"standard","findings_index":[{"id":"F1","structure":{"claims":8,"claims_by_group":{"comparisons":0,"experience":0,"questions":2,"restated":2,"views":4},"has_counterview":true,"limitations":3,"links":{"context":2,"support":9},"ma_question":true,"named_voices":4,"passages":7,"sources":5,"sources_by_kind":{"commentary":4,"registry":1}},"title":"Enthusiasm for personalization remains conditional on improving cure in resected NSCLC"},{"id":"F2","structure":{"claims":10,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":5,"views":4},"has_counterview":true,"limitations":3,"links":{"context":5,"support":14},"ma_question":true,"named_voices":4,"passages":6,"sources":6,"sources_by_kind":{"commentary":4,"media":1,"registry":1}},"title":"The postoperative add-on strategy is distinct from the question of outperforming neoadjuvant therapy"},{"id":"F3","structure":{"claims":3,"claims_by_group":{"comparisons":0,"experience":0,"questions":2,"restated":0,"views":1},"has_counterview":true,"limitations":3,"links":{"context":2,"support":3},"ma_question":true,"named_voices":3,"passages":3,"sources":2,"sources_by_kind":{"commentary":2}},"title":"Conceptual promise and evidentiary credibility attract different challenges"},{"id":"F4","structure":{"claims":6,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":4,"views":1},"has_counterview":false,"limitations":4,"links":{"context":1,"support":8},"ma_question":true,"named_voices":2,"passages":3,"sources":3,"sources_by_kind":{"commentary":2,"media":1}},"title":"Cross-center recruitment and infusion-chair burden are practical discussion points"},{"id":"F5","structure":{"claims":1,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":0,"views":0},"has_counterview":false,"limitations":3,"links":{"context":0,"support":1},"ma_question":true,"named_voices":1,"passages":1,"sources":1,"sources_by_kind":{"commentary":1}},"title":"An exploratory combination question explicitly sets staging aside"},{"id":"F6","structure":{"claims":7,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":5,"views":1},"has_counterview":false,"limitations":6,"links":{"context":2,"support":10},"ma_question":true,"named_voices":3,"passages":4,"sources":4,"sources_by_kind":{"commentary":4}},"title":"Wider platform and market comparisons should not be read as clinical alternatives for the trial population"}],"medical_affairs_question":"What evidence would establish a meaningful improvement in cure and clarify the strategy’s place alongside perioperative options?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Can personalization improve cure in resected NSCLC?"},{"id":"section-2","level":2,"title":"Postoperative intensification is not a demonstrated replacement for neoadjuvant therapy"},{"id":"section-3","level":2,"title":"Different objections concern conceptual relevance and verifiable evidence"},{"id":"section-4","level":2,"title":"Recruitment and administration burden enter the practical discussion"},{"id":"section-5","level":2,"title":"The exploratory combination analogy deliberately ignores staging"},{"id":"section-6","level":2,"title":"Platform comparisons extend beyond the target treatment decision"},{"id":"section-7","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[],"id":"T1","label":"Primary endpoint: Disease- Free Survival (DFS)"},{"findings":[],"id":"T2","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F2","shared_claims":5},{"id":"F4","shared_claims":1}],"id":"T3","label":"Population and setting"},{"findings":[{"id":"F2","shared_claims":6},{"id":"F4","shared_claims":1}],"id":"T4","label":"The comparison"},{"findings":[],"id":"T5","label":"Safety and tolerability"},{"findings":[{"id":"F2","shared_claims":1},{"id":"F4","shared_claims":2}],"id":"T6","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-29T04:26:11.121985Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-29T05:35:33Z","record_hash":"e73db7fef57a9e8550bd5d24ace2300c7bbb79511b7908df11c76a45f8ea9590","release_hash":"dba33071814758551189528e916a4745cdbb820259737febb9446b724081e7bc","report_id":"erudio-nct06077760","run_id":"12ba4041-b222-4feb-bdf5-5199a8190ce8","schema_version":"5.0","slug":"interpath-002-06077760","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"INTerpath-002 asks whether adding a personalized vaccine to pembrolizumab after complete resection of stage II, IIIA or IIIB (N2) NSCLC improves disease-free survival. In the sources reviewed for this edition, an X poster questions its positioning against neoadjuvant therapy. One medical oncologist expresses enthusiasm for personalization, while another X poster raises administration-burden concerns. Whether the strategy meaningfully improves cure remains open for that oncologist.","meta_description":"50 sources screened · 36 verified statements (8 from clinicians verified by NPI or staff page) from 20 sources · 6 findings. Updated Oct 29, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-3a67e81aaa2f843c0523"],"id":"F2","paraphrase":"An X thread identifies the treatment combination under discussion as an mRNA cancer vaccine with pembrolizumab.","source_channel":"x_thread","source_date":"2026-09-10","title":"The postoperative add-on strategy is distinct from the question of outperforming neoadjuvant therapy"},{"cited_claim_ids":["claim-248514b894f9525c31c3"],"id":"F1","paraphrase":"An X post by a medical oncologist describes the phase III study population as patients with surgically resected stage II–IIIB NSCLC.","source_channel":"x_thread","source_date":"2026-05-22","title":"Enthusiasm for personalization remains conditional on improving cure in resected NSCLC"}]},"publication":{"approved_at":"2026-10-29T05:35:33Z","approved_by":"Erudio publisher","corrections":[{"affected_ids":[],"date":"2026-10-29T05:45:46Z","summary":"Corrected to match the delivered report: per-finding counts; the limitations; the sample findings; source quotations and links in the paid report. The trial's name is spelled as its investigators write it, “INTerpath-002” (NCT06077760), outside quotations (was “Interpath”). The trial's registration date is now stated."}],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":50},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Some clinician views in the sources used in this report are not yet captured as evidence in this edition.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","50 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","The sources reviewed for this edition are not a representative sample of HCP opinion. Reposts, repeated posts and source counts do not establish additional independent clinical voices or consensus.","No full protocol, exact-trial results publication or exact product label was available in the reviewed material. The report cannot provide a complete methods, regulatory, efficacy or safety assessment.","Melanoma findings, including first impressions of leaked data, are used by contributors as rationale or context. They are not INTerpath-002 outcomes, and uncertainty from the INTerpath-009 residual-disease setting is not a direct assessment of this trial.","Some contributors have no confirmed clinical role. Descriptions such as MD or surgical oncologist are attributed source descriptions where noted, not independently confirmed credentials; confirmed personal identity does not increase the certainty of an opinion.","Enrollment is described only at the time of the relevant recording, without an identified speaker. It should not be treated as confirmation of current trial status.","Not yet captured in this edition: a view on perioperative immunotherapy evidence and testing, specialist capacity and access barriers in resectable non-small-cell lung cancer."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":1,"regulatory":0,"x_thread":17,"x_video":0,"youtube":2},"by_evidence_role":{"commentary":19,"methods":1},"count":20,"evidence_window":{"end":"2026-10-25","start":"2023-12-12"},"retrieval_snapshot":"2026-10-29T03:24:20.730215Z","timeline":[{"count":1,"week":"2023-W50"},{"count":1,"week":"2024-W19"},{"count":1,"week":"2024-W23"},{"count":1,"week":"2024-W26"},{"count":1,"week":"2024-W44"},{"count":1,"week":"2024-W50"},{"count":1,"week":"2025-W17"},{"count":1,"week":"2025-W40"},{"count":1,"week":"2026-W18"},{"count":1,"week":"2026-W21"},{"count":3,"week":"2026-W34"},{"count":1,"week":"2026-W37"},{"count":1,"week":"2026-W38"},{"count":1,"week":"2026-W42"},{"count":3,"week":"2026-W43"}],"undated_sources":1},"quote_policies":[{"id":"clinicaltrials:NCT06077760:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT06077760:context","quote_policy":"short_quote_link_out"},{"id":"openfda:097d166f-b73b-41d3-9b37-7653cd2a0c41:20260731","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-6vwezbhj7wwowu4sbur5npjk-3mgxbhlzqwc2v","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-fraujaa5htqy5foevaon4ccn-3lcbomiupok2v","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-llgfbjvsqkaicezsf7mzjxr3-3kgjgw5bosz2s","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-mdocvky3thypleu26gbyjgex-3khrqjsfmau2y","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1712104084918976826:fbba9c99-fb5b-4613-9e95-0465b3774579","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1734178236341383376:1c1b53d0-a6f3-4b90-a515-c163b7ad7bc9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1734178629137920145:5ff2eeda-84ac-431e-b843-8f8797277692","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1734178742594134330:8eba340b-ea48-4e89-832a-00c0951ad0e8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1734178971816755320:64871e76-693f-4f55-8763-82e76ea8cb24","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1734179120827744271:db4f5d51-51a2-4b1f-85e8-734882f2707f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1734183425710358630:434dbf31-ee8d-4676-ae3e-553a48e7e284","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1734201638842241400:9fafa169-3240-49bd-80e2-b985c2e14b39","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1734222790650208360:f489a677-a03b-4d69-ba59-81780e713835","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1734223451416899834:b8580319-cda0-4e01-a0ec-2e4c2dd4a894","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1734268305328762994:3e613a98-ad6b-49d2-8a40-1768975e871e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1734382527538766303:c121a635-c4b1-4755-9f71-7737b4f72dd3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1734556376850890998:79dd3cf9-1bc0-445b-83ac-e433d6c57fc9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1734560945853329416:8c69d268-a46f-4cc4-950d-226993b36bfb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1751201273318175090:f7cc9eb1-59f2-4372-9b82-0644f7a29bc0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1776312842955960540:9778c085-782c-424e-bb5f-90379e530d81","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1777233325045772656:43922e79-1ac6-4c43-9d49-a74205bac1a9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1785722844183146602:449fcc1d-1d12-4ff2-9c7e-8fdffdf74cad","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1798320003688829302:15386c30-f028-401f-b8da-b62676e8c891","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1806873854129688904:e5732d7c-045c-4059-9233-69adba2f42ef","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1833211445091438684:4851eeb2-dad4-4c29-be8f-476a58d74292","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1850858722312007915:0dbcad3d-e4a2-487f-b841-c2077e386442","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1866209115250246117:596abc6c-9835-43b2-9bf4-5796ece80aa0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1897762462184648960:4b34aed7-54eb-4ce7-8218-6b836abd378a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1916151979421663743:12e39511-e94d-4869-8961-95fab640adb5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1964750721934643277:18bb8d9a-c828-47ed-aa70-71ca6000d626","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1973035949190984050:ec16e75c-d076-4967-b9b3-d7ec0312d2ee","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2032484727593279753:a2cad7f0-0470-4978-9746-3baf9aa4603c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2037801698480001345:5f3071e9-8937-46a7-9502-39431fc6bc95","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2050951071082623328:18f38e52-eafa-44a3-a31e-7661d89288b1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2057916610069827778:48280c1a-4d01-4ef4-a3f6-3080a76ab9ef","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2058914935862948270:531c8003-ffe2-46c1-bbc4-486bbc3ab2aa","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2090067174069240289:5a105f6d-96fc-46da-a117-501594246256","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2090069927843533123:0714b4af-7744-4ecb-88f6-4b82b8882124","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2090070108387360827:1900b827-437d-4823-a72c-77015c62c99a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2090190664713539647:85430323-d4a9-4462-bae0-001ce4cd1014","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2090332612376056298:a799dea1-33d5-4f9d-8afb-12ede2101c70","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2090335942787911870:4bc67f8f-d8ba-42cc-835f-0551396fd933","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2098056908447912218:e1098711-3668-479d-94a0-cc2af60dfd63","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2110883208526971325:cffc4919-353b-4985-b7d4-c95f29c204a8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112566331178418214:81c915e6-9b4d-49b8-9d11-784b62584d74","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113374750978269285:84f9f17b-3555-456c-aabf-ee54921182c3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114038207780196468:84aa9fec-251b-4ac5-9742-c90364dbdb54","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114450526519558409:4577ce65-2b98-452f-93ea-90f7212d9996","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:59eGtn4KxMs","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:yUnO7z-enCw","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":4,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":44,"x_video":0,"youtube":2},"by_evidence_role":{"commentary":50},"count":50,"evidence_window":{"end":"2026-10-25","start":"2023-10-11"},"retrieval_snapshot":"2026-10-29T03:24:20.730215Z","timeline":[{"count":1,"week":"2023-W41"},{"count":14,"week":"2023-W50"},{"count":1,"week":"2023-W51"},{"count":1,"week":"2023-W52"},{"count":1,"week":"2024-W04"},{"count":1,"week":"2024-W14"},{"count":1,"week":"2024-W15"},{"count":1,"week":"2024-W19"},{"count":2,"week":"2024-W23"},{"count":1,"week":"2024-W26"},{"count":1,"week":"2024-W37"},{"count":1,"week":"2024-W44"},{"count":1,"week":"2024-W48"},{"count":1,"week":"2024-W50"},{"count":1,"week":"2025-W10"},{"count":1,"week":"2025-W17"},{"count":1,"week":"2025-W36"},{"count":1,"week":"2025-W37"},{"count":1,"week":"2025-W40"},{"count":2,"week":"2026-W11"},{"count":1,"week":"2026-W12"},{"count":1,"week":"2026-W13"},{"count":1,"week":"2026-W18"},{"count":1,"week":"2026-W21"},{"count":1,"week":"2026-W22"},{"count":6,"week":"2026-W34"},{"count":1,"week":"2026-W37"},{"count":1,"week":"2026-W38"},{"count":1,"week":"2026-W42"},{"count":4,"week":"2026-W43"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: intismeran autogene","status":"unmapped"},{"brand_names":["Keytruda"],"label":"pembrolizumab","slug":"pembrolizumab"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Non-small cell lung cancer","slug":"non-small-cell-lung-cancer"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"INTerpath-002","aliases":["INTerpath-002","A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)","A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With Resected Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer (INTerpath-002)"],"brief_title":"A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)","collaborators":["ModernaTX, Inc."],"conditions":["Non-small Cell Lung Cancer"],"enrollment":{"count":868,"type":"ESTIMATED"},"interventions":[{"name":"Intismeran autogene","synonyms":["mRNA-4157","V940"],"type":"BIOLOGICAL"},{"name":"Pembrolizumab","synonyms":["MK-3475","KEYTRUDA®"],"type":"BIOLOGICAL"},{"name":"Placebo","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"OTHER"}],"nct_id":"NCT06077760","official_title":"A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With Resected Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer (INTerpath-002)","overall_status":"ACTIVE_NOT_RECRUITING","phase":["PHASE3"],"primary_completion_date":{"date":"2030-06-25","type":"ESTIMATED"},"primary_endpoints":[{"description":"DFS is defined as the time from randomization to any recurrence (local, locoregional, regional or distant), occurrence of new primary NSCLC, as assessed by the investigator, or death due to any cause, whichever occurs first.","measure":"Disease- Free Survival (DFS)","timeFrame":"Up to ~78 months"}],"registered_date":{"date":"2023-10-11","type":"ACTUAL"},"registry_last_updated":"2026-09-18","registry_url":"https://clinicaltrials.gov/study/NCT06077760","short_name":"INTerpath-002","short_name_basis":"registry_acronym","sponsor":"Merck Sharp & Dohme LLC","start_date":{"date":"2023-12-06","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"V940-002","type":"sponsor_study_id"},{"domain":"EU CT","id":"2023-504923-20-00","type":"registry"},{"domain":"UTN","id":"U1111-1290-3969","type":"registry"},{"domain":"jRCT","id":"jRCT2061240063","type":"registry"},{"domain":"PHRR","id":"PHRR240705-007252","type":"registry"}],"study_type":"INTERVENTIONAL"}}}